SEATTLE, Nov. 7, 2018 /PRNewswire/ -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system (CNS) disorders with unmet medical needs, today announced the appointment of Ellen A. Lubman as Chief Business Officer. In her role, Ellen's primary responsibilities are to...

Study to Establish Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Olanzapine Delivered via Precision Olfactory Delivery (POD®) Device SEATTLE, August 29, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biopharmaceutical company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced the first subject has been dosed in a...

Safety and Tolerability of POD-DHE (STOP-301) Trial to Explore Safety and Tolerability of Long-Term Intermittent Use of Intranasal Dihydroergotamine Mesylate Delivered via Precision Olfactory Delivery (POD®) Device STOP-301 Trial Recruiting More Quickly Than Expected, Company On-Track With 2019 NDA Filing SEATTLE, August 22, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biopharmaceutical company...

SEATTLE, July 16, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that Lynn C. Gold, Ph.D., has joined the Company as the Senior Vice President of Regulatory Affairs. In this capacity, Gold has extensive oversight of regulatory...

SEATTLE, June 26, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced new data from the Company’s investigational drug INP104 for acute migraine will be presented at the American Headache Society’s 60th Annual Meeting, June 28...

SEATTLE, June 22, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it may proceed with its clinical investigation of INP104, a novel, dihydroergotamine...

Study to Explore the Therapeutic Benefit of Intranasal Levodopa in Parkinson’s Disease OFF Reversal (THOR 201) SEATTLE, May 31, 2018 -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced the initiation of a Phase IIa study designed to explore...

Novel, Intranasal Dihydroergotamine Dosed via Precision Olfactory Delivery, or POD™, Device Achieved Primary Outcome of Bioavailability, Safety Study Marks First of Four Impel Clinical Trial Read Outs Planned for 2018 SEATTLE, Feb. 7, 2018  -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today...

Study to Explore Bioavailability and Safety of Novel, Intranasal Dihydroergotamine Delivered via Precision Olfactory Delivery™ Technology SEATTLE, October 31, 2017 -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that the first patient was dosed in the recently-initiated...

New CEO will lead Impel’s unique CNS pipeline to the clinic and potential commercialization Seattle, WA—October 03, 2017—Impel NeuroPharma, Inc., a Seattle based biotechnology company, announced the appointment of veteran biotech executive Jon Congleton as the company’s new President and Chief Executive Officer (CEO). Impel is developing first-in-class intranasal drug...